Can Gilead Stock Outrun Regeneron In The Next Rally?

Regeneron stock increased by 19% over the past month, driven by strong third-quarter earnings. But is Gilead the better pick?
MedPage Today on MSN

Regulatory T-Cell Drug Promising for Eczema, With Hint for Asthma as Well

For the primary endpoint, Eczema Area and Severity Index (EASI) improved by 53-61% in a dose-dependent manner across the ...
TipRanks on MSN

REGN, GMAB, ARWR: Which Healthcare Stock Is Best Buy Ahead of U.S. Drug Approvals This Nov?

Several pharmaceutical companies awaiting a decision from U.S. authorities on their drug applications are set to get them ...
pharmaphorum

Amgen, AZ's Tezspire challenges Dupixent in nasal polyps

Amgen and AstraZeneca's Tezspire has claimed FDA approval as a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP), its second indication after severe asthma. The anti-TSLP antibody has ...
Des Moines Register

Parents of child with rare disease worry after NIH cuts grant that provides him treatment

Charlie Evans, 13, who suffers from severe food allergies and eosinophilic esophagitis (EoE), takes part in an NIH-funded study at Cincinnati Children's hospital. The NIH dismissed the hospital's ...